Symphogen has raised a total of €249 million to date in equity capital through an international investor syndicate including Essex Woodlands Health Ventures (USA), Novo A/S (DK), PKA (DK), LD (DK), Danica Pension (DK), Sunstone Capital (DK), Gilde Healthcare Partners (Netherlands), Tri-Takeda (Japan) and Genentech (USA).
Symphogen Investors:
Essex Woodlands Health Ventures
Novo A/S
Danica Pension
PKA
Sunstone Capital
Gilde Healthcare Partners
Tri-Takeda
Genentech
